TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06742801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Onyx™ Liquid Embolic System
Description: The proposed indication for Onyx™ LES is: Onyx™ LES is indicated for the embolization of arterial hemorrhage in the peripheral vasculature.
Study: NCT06135051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diadem prototype
Description: The device delivers low-intensity ultrasonic waves into specific brain targets.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Diadem prototype
Description: The device delivers low-intensity ultrasonic waves into specific brain targets.
Study: NCT05339035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training based on IMB model, motivational interview technique, hippotherapy program
Description: In the first stage of the research, the Digital Game Addiction Scale for Children will be applied to the entire universe and participants with a digital game addiction score of 73 and above will be determined. According to the criteria of inclusion in the research, students will be informed and those who volunteer to participate in the study will be determined and listed. After the experimental and control groups are determined, the participants will be contacted and data collection forms will be applied. The students in the experimental group will be trained according to the IMB model, the students in the experimental group will be given a 6-session motivational interview program and the students will be taken to the hippotherapy program, which lasts 1 hour once a week for 8 weeks. Hippotherapy applications will be carried out at the horse farm in Amasya, accompanied by expert horsemen.
Study: NCT06237309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5381
Description: Single dose intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5381
Description: Single dose intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5381
Description: Single dose intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5381
Description: Single dose intravenous (IV) infusion
Study: NCT06477510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal therapy
Description: change in self perception of esthetics and clinical periodontal parameters will be assessed after non-surgical periodontal therapy.
Study: NCT05068895

Intervention type: OTHER
Intervention: liquid chromatography-mass spectrometry
Description: Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography-mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and repro- ducibility.
Study: NCT06237309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5381
Description: Single dose intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5381
Description: Single dose intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5381
Description: Single dose intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5381
Description: Single dose intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5381
Description: Single dose intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose IV infusion
Study: NCT04432441

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic physical exercise program for scapulo-humeral stabilitation
Description: This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation during a month

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic physical exercise program for scapulo-humeral stabilitation + electrostimulation
Description: This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation added electrostimulation during a month
Study: NCT06237309

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose IV infusion
Study: NCT05568043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPD Transitions of Care Intervention Bundle: Virtual Interventions
Description: The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. Virtual interventions included in the bundle may consist of: phone or e-consults for medication reconciliation, virtual teach-to-goal \[V-TTG\] or tele-TTG inhaler education, and post-discharge phone call communication and/or texts/ and/or electronic portal use, among others.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPD Transitions of Care Intervention Bundle: Virtual Interventions
Description: The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. Virtual interventions included in the bundle may consist of: phone or e-consults for medication reconciliation, virtual teach-to-goal \[V-TTG\] or tele-TTG inhaler education, and post-discharge phone call communication and/or texts/ and/or electronic portal use, among others.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPD Transitions of Care Intervention Bundle: In-Person Interventions
Description: The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. In-person interventions include face-to-face general COPD education, inhaler education, medication reconciliation, post-discharge clinic visits, community health worker home visits, pulmonary rehabilitation, smoking cessation programs, among others.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPD Transitions of Care Intervention Bundle: In-Person Interventions
Description: The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. In-person interventions include face-to-face general COPD education, inhaler education, medication reconciliation, post-discharge clinic visits, community health worker home visits, pulmonary rehabilitation, smoking cessation programs, among others.
Study: NCT05721885

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: nutrition management
Description: Nutritional management was performed by clinical pharmacists and registered dietitians to develop nutritional intervention strategies based on patient clinical assessment and nutritional assessment. PG-SGA score was 0-3 points, and diet guidance was given. PG-SGA score \> 4 points, artificial nutrition intervention was carried out, and the way and amount of nutritional intervention were clarified to achieve the final daily energy and protein target requirements. Nutritional interventions and assessments were adjusted over time.
Study: NCT06498271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized and automated digital coaching using a mobile application
Description: Participants allocated to the experimental group will be invited to download a smartphone application which will appraise their motivation and automatically propose: 1) exercises to be performed at home and adapted to their pain levels; 2) audio recordings for pain management; and 3) educational and coaching content adapted to their motivation. In addition, the smartphone application enables users to plan their home exercises
Study: NCT05451342

Intervention type: DIAGNOSTIC_TEST
Intervention: Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling
Description: Blood samples and BALD samples will be collected for further integrated transcriptomics, metabolomics, lipidomics analysis, and exosome extraction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling
Description: Blood samples and BALD samples will be collected for further integrated transcriptomics, metabolomics, lipidomics analysis, and exosome extraction.
Study: NCT05969418

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter
Description: Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter before and after ANTI-VEGF treatment

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter
Description: Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter before and after ANTI-VEGF treatment
Study: NCT04529473

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eubacterium hallii
Description: Eubacterium hallii, ≥ 1x10\^9 live bacterial cells (per capsule)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are identical to the active treatment
Study: NCT06483204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medrol 4 MG Oral Tablet Includes Medrol Dosepak
Description: Medrol tapered dosepak given to experimental arm patients to determine if there is a significant difference in pain, nausea, edema and ecchymosis outcomes in the postoperative period after a functional rhinoplasty procedure.
Study: NCT05482932

Intervention type: DIAGNOSTIC_TEST
Intervention: Health-related physical fitness assessment
Description: Participants will complete several questionnaires and perform multiple health-related physical fitness tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Health-related physical fitness assessment
Description: Participants will complete several questionnaires and perform multiple health-related physical fitness tests
Study: NCT06442761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motixafortide
Description: Given Subcutaneously (under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motixafortide
Description: Given Subcutaneously (under the skin).
Study: NCT06004752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Cyclosporine was taken orally at 3-5mg/kg bid was administered to maintain the trough concentration at 100-200 μg/ml
Study: NCT05646472

Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty multidimensional assessment
Description: Each Centre will administer SUNFRAIL frailty assessment tool to the enrolled older adults and, according to the specific alerts triggered by the answers provided, older adults will be subjected (at the same time or subsequently) to one or more validated in-depth tests (already included in the SUNFRAIL+ platform) in order to perform further diagnostic or dimensional evaluations.~During the observation phase, subjects will be given different health promotion activities, depending on the assessment.~During the follow-up phase, 6 months after enrolment, SUNFRAIL tool and in-depth tests will be administered again. In addition, during the follow up, the extent to which exposure to interventions has influenced the quality of life of older adults will be measured and the number of users enrolled by territorial services, based on user care needs. In addition, the level of satisfaction and usability of the SUNFRAIL+ solution by health and social care professionals will be measured.
Study: NCT06197399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Detethering Surgery
Description: Detethering surgery, or cord untethering, is a conventional surgical approach for treating tethered cord syndrome (TCS). It involves releasing the spinal cord from its abnormal attachment. During the surgical procedure, once the tethered area is identified, careful microsurgical techniques are used to separate the spinal cord from the surrounding abnormal tissue. This operation aims to alleviate the symptoms of TCS by removing the cause of tension on the spinal cord.
Study: NCT06004752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Avatrombopag was administrated at 40 mg/d and increased by 20 mg/d during the biweekly follow-up if platelet was not 20 × 109/L higher than baseline. AVA dose was gradually reduced if PLT ≥ 150 × 109/L. The maximum dose was 60 mg/d, while the minimum was 20 mg/week.
Study: NCT06560320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: Virtual Reality(VR) Glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses before starting the application and it continued until the end of the vaccination procedure.
Study: NCT05234177

Intervention type: OTHER
Intervention: Observation
Description: No intervention
Study: NCT06177067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Given by mouth (capsule or liquid solution) or liquid solution by Nasogastric tube (NG) or Gastrostomy tube (G-tube)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by mouth (tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given intravenously (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal (IT) chemotherapy
Description: Given intrathecal (IT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
Study: NCT06197399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Column Shortening Surgery
Description: Spinal column shortening surgery is an innovative surgical approach that involves reducing the tension on the spinal cord by shortening the spinal column, effectively untethering the spinal cord indirectly. The procedure primarily involves the thoracolumbar region.The choice of this region for intervention offers several advantages: it is a safe distance from the previous detethering surgery area; it is closer to the conus medullaris of the spinal cord, ensuring better treatment effectiveness; and the impact on spinal mobility is minimal after internal fixation at this region. This technique is designed to alleviate TCS symptoms while minimizing the risk of postoperative cerebrospinal fluid (CSF) leakage, which is a common complication in direct untethering procedures for recurrent cases. All procedures will be conducted by trained and experienced neurosurgeons following standardized protocols.
Study: NCT05087823

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid Challenge
Description: For the lipid challenge, participants consume 100 grams of a long chain triglyceride emulsion in the form of liquid drink, which is the commercially available brand called Calogen, from Nutricia, Inc.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose Challenge
Description: For the glucose challenge, participants consume 75 grams of glucose in 200 milliliters of water, which is the World Health Organization (WHO) recommended drink for the Oral Glucose Tolerance Test.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed Meal Challenge
Description: For the mixed-meal challenge, participants consume 237 milliliters of the Ensure Enlive nutrition drink , which contains 11 grams of fat, 22 grams of sugar and 20 grams of protein.
Study: NCT04522102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Start antiplatelet monotherapy
Description: Start one antiplatelet drug, be available in local standard clinical practice, chosen by patient's physician pre-randomisation
Study: NCT06177067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
Study: NCT05551429

Intervention type: BEHAVIORAL
Intervention: Invitation to the CR
Description: 1. Oral and written information emphasise the benefits of cardiac rehabilitation in terms of treatment of heart diseases, increasing functional capacity, reducing morbidity and mortality, and enhancing secondary prevention.~2. Introducing the scope and method of administration of CR to patients.~3. Setting up the appointment for the initial CR session four weeks later.
Study: NCT05348395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental diet
Description: Participants that successfully complete the run-in phase will participate in the experimental diet for 8 weeks of feeding. The Participants' adherence will be monitored using direct observation, written daily food diaries, and food waste inventory (i.e., participants are trained to estimate portion of uneaten foods). Participants will be asked to eat one meal onsite 2-3 weekdays (e.g., Monday, Wednesday, and Friday), at which time they will receive meals and snacks for the remainder of that day and enough until the next scheduled visit.
Study: NCT05760430

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PVE+cTACE+Camrelizumab+Apatinib
Description: After cTACE, 3 mg/kg of Camrelizumab was injected intravenously once every three weeks+250 mg of Apatinib mesylate tablets were taken orally once a day. PVE was performed on the half liver with the largest tumor load 2 weeks after CTACE.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: cTACE+Atirizumab+Bevacizumab
Description: After cTACE, 1200 mg of Atirizumab+15 mg/kg of Bevacizumab was injected intravenously every three weeks.
Study: NCT06183515

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP group: postoperative CPAP support, non-CPAP group: oxygen 3 liters per minute (L/min) either via mask for those who were extubated or through a T-piece for those with a trash
Description: The effect of CPAP was prevent atelectasis after apnoeic ventilation during the procedure and to reduce post-procedural airway problems.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP group: postoperative CPAP support, non-CPAP group: oxygen 3 liters per minute (L/min) either via mask for those who were extubated or through a T-piece for those with a trash
Description: The effect of CPAP was prevent atelectasis after apnoeic ventilation during the procedure and to reduce post-procedural airway problems.
Study: NCT05906303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine and Sodium Benzoate Injection
Description: Provide caffeine to shorten second stage of labor and augment pushing efforts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Provide normal saline to serve as a placebo
Study: NCT06329518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezafungin
Description: After receipt of Rezafungin, blood samples will be collected at various time points to determine the pharmacokinetics of Rezafungin.
Study: NCT06699797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acclaim Cochlear Implant
Description: Participants with the Acclaim CI device will be tested during follow-up with their hearing results compared to baseline (before the device implant procedure).
Study: NCT06719778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two-stage nutritional therapy concept
Description: 1. Stabilization phase:~   application of a mostly vegetarian Mediterranean wholefood diet and strategies from a comprehensive lifestyle modification concept.~2. Elimination phase:~additional omission diet avoiding the food that was identified by CLE to induce an intestinal barrier defect.
Study: NCT06725212

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Water Vapor Thermal Ablation
Description: The water vapor thermal ablation system injects thermal energy in the form of water vapor into the hyperplastic prostate tissue in controlled doses. The injected water vapor quickly disperses through the gaps between tissue cells. When water vapor comes into contact with tissue, it cools and condenses immediately. The stored heat energy is released, denaturing the cell membrane, causing cell death and eventually being absorbed or shed by the body and excreted through urination, thus improving the lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Water Vapor Thermal Ablation
Description: The water vapor thermal ablation system injects thermal energy in the form of water vapor into the hyperplastic prostate tissue in controlled doses. The injected water vapor quickly disperses through the gaps between tissue cells. When water vapor comes into contact with tissue, it cools and condenses immediately. The stored heat energy is released, denaturing the cell membrane, causing cell death and eventually being absorbed or shed by the body and excreted through urination, thus improving the lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cystoscopy
Description: Cystoscopy is a procedure that allows the doctor to examine the lining of patient's bladder and the tube that carries urine out of the body (urethra). A hollow tube (cystoscope) equipped with a lens is inserted into your urethra and slowly advanced into the bladder.
Study: NCT06730360

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MTA Pulpotomy without photobiomodulation
Description: This intervention involves the application of Mineral Trioxide Aggregate (MTA) to the pulp chamber after the removal of the coronal pulp tissue in first permanent molars with irreversible pulpitis. The procedure is performed without the use of photobiomodulation (low-level laser therapy). The MTA is placed as a seal to preserve the vitality of the remaining radicular pulp.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MTA Pulpotomy with Photobiomodulation (LLLT)
Description: This intervention combines MTA pulpotomy with photobiomodulation (low-level laser therapy). After performing the MTA pulpotomy, low-level laser therapy is applied to the pulp stumps to reduce inflammation, promote healing, and modulate pain. The laser therapy uses specific wavelengths of light to stimulate cellular activity and enhance the regeneration of pulp tissue.
Study: NCT06739772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Self-Sampling and Behavior Intervention
Description: Participants in the intervention group will receive HPV self sampling and behavioral intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participants in the intervention group will receive HPV self sampling and behavioral intervention
Description: Received enhance standard care